Experienced in Angiosarcoma of the Liver

Dr. Sridhar R. Bolla

Hendricks County Hospital
Danville, IN
Experienced
in Angiosarcoma of the Liver
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Sridhar Bolla is a Hematologist Oncology specialist and a Hematologist in Danville, Indiana. Dr. Bolla and is rated as an Experienced provider by MediFind in the treatment of Angiosarcoma of the Liver. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, Lung Adenocarcinoma, and Bone Marrow Aspiration. Dr. Bolla is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Putnam County Hospital
Hendricks Regional Health
Iu Health West Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Anthem
  •  CareSource
  •  Humana

Locations

HENDRICKS COUNTY HOSPITAL
1000 E Main St, Danville, IN 46122
317-272-7519
Other Locations
HENDRICKS COUNTY HOSPITAL
8244 E Us Hwy 36 1320, Avon Internal Medicine, Avon, IN 46123
317-272-7519
HENDRICKS COUNTY HOSPITAL
1152 E Us Hwy 36, Hendricks Regional Hlth Bainbridge, Bainbridge, IN 46105
765-522-1889
HENDRICKS COUNTY HOSPITAL
100 Hospital Ln, Danville, IN 46122

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: M7824, Durvalumab, Etoposide, Pemetrexed, Carboplatin, Paclitaxel, Cisplatin
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
View 2 Less Clinical Trials

1 Total Publications

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel.
Journal: Gynecologic oncology case reports
Published: March 25, 2013
Similar Doctors
Expertise in
58
conditions
Dr. Subhash C. Sharma
Hematology Oncology
Expertise in
58
conditions
Dr. Subhash C. Sharma
Hematology Oncology
3649 Walnut Hill Ct, 
Greenwood, IN 
 (20.6 mi)
317-851-9251
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Subhash Sharma is a Hematologist Oncology provider in Greenwood, Indiana. Dr. Sharma and is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma of the Liver. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Acute Promyelocytic Leukemia, Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Sharma is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile